HollyMeanyMD
Pediatric Hematology & Oncology • Washington, DCAssociate Professor, Pediatrics, G Washington University School of Medicine & Hlth Sci
Dr. Meany is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Ave Nw
Washington, DC 20010Phone+1 202-884-2140
Education & Training
Children's National Hospital/George Washington UniversityFellowship, Pediatric Hematology/Oncology, 2003 - 2006
Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics, 2000 - 2003
Ohio State University College of MedicineClass of 2000
Certifications & Licensure
VA State Medical License 2006 - 2026
MD State Medical License 2022 - 2025
DC State Medical License 2003 - 2024
OH State Medical License 2000 - 2004- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Start of enrollment: 2005 Dec 01
- Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Start of enrollment: 2011 Dec 01
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Start of enrollment: 2014 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsPhase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsHolly J. Meany, Brigitte C. Widemann, Pamela S. Hinds, Rochelle Bagatell, Suzanne Shusterman
Pediatric Blood & Cancer. 2021-08-12 - Epithelioid Sarcoma in a Young Child: A Case Report and Literature Review.Joseph H Talbet, Jennifer L. McGrath, Monica Manrique, Esperanza Mantilla-Rivas, Holly J. Meany
Plastic and Reconstructive Surgery. Global Open. 2021-02-01 - 32 citationsImmunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I StudyAmy B. Hont, C. Russell Cruz, Robert Ulrey, Barbara O’Brien, Maja Stanojevic
Journal of Clinical Oncology. 2019-07-29
Press Mentions
Tumor-Associated Antigen Cytotoxic T Cells in Relapsed or Refractory Solid TumorsAugust 5th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
